Basilea Pharmaceutica AG (BSLN.S) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Sadif Analytics Prime
$10.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Basilea Pharmaceutica AG confirms FY 2014 guidance


Thursday, 14 Aug 2014 01:25am EDT 

Basilea Pharmaceutica AG:Confirms its unchanged guidance.Total operating expenses for 2014 are estimated at 8 to 9 million Swiss francs on average per month.The operating loss in 2014 is estimated at 4 to 5 million Swiss francs on average per month.